Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB-201 in mild to moderate ulcerative colitis
2012-003974-18Phase 2Completed
- Sponsor
- VBL Therapeutics
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing VB-201 with Placebo (2 arms). Primary endpoint: Safety. Started Sep 2012; status: completed.
02
Drugs
VB-201
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2012-003974-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003974-18.